摘要
目的:观察非小细胞肺癌患者外周血T淋巴细胞活化抗原CD3+/CD25+和CD3+/HLA-DR+的表达,进一步探讨患者的免疫功能。方法:应用流式细胞双色免疫荧光标记技术对58例肺癌患者外周血T淋巴细胞活化抗原CD3-PE和CD25/HLA-DR-FITC表达进行荧光免疫检测,并与良性病变组(n=29)和正常对照组(n=29)进行对比研究。结果:58例肺癌患者外周血T淋巴细胞中CD3+/CD25+和CD3+/HLA-DR+表达明显低于良性病变组和正常对照组(P<0.01);良性病变组和正常对照组之间无显著性差异。肺癌伴淋巴结转移CD3+/CD25+和CD3+/HLA-DR+低于不伴淋巴结转移者(P<0.01);Ⅲ期、Ⅳ期和Ⅰ期、Ⅱ期之间CD25和HLA—DR表达,有显著性差异(P<0.01);CD3+/CD25+和CD3+/HLA—DR+表达与肺癌组织学分级及年龄有明显相关性(P<0.05或P<0.01);与鳞癌和腺癌及患者的性别没有相关性。手术后外周血CD3+/CD25+和CD3+/HLA-DR+的表达高于手术前(P<0.01或P<0.05);术后一月后外周血中CD3+/CD25+和CD3+/HLA-DR+的表达水平与术后一周时的表达水平相比无显著性差异。结论:应用流式细胞仪检测外周血CD3+/CD25+和CD3+/HLA-DR+的表达水平对了解患者的免疫状态、病情判断、预后评估及进行免疫治疗具有重要的意义。
Objective: To analyze expression of T lymphocyte activation antigen in peripheral blood of patients with non-small cell lung cancer and to study changes of its immunity function. Methods: The lymphocyte from the peripheral blood in patients with non-small cell lung cancer were immunologically double fluorescent labeled by CD25/HLA-DR-FITC were determined by flow cytome-try. 29 benign lesions and 29 normal donors served as controls. Results: Peripheral blood CD3 + /CD25 + and CD3 + /HLA-DR + in T lymphocyte with lung cancer were significantly lower than those in normal controls (P <0. 01 ). Lung cancer with lymph node metastasis showed lower expression of CD3 + /CD25 + and CD3 + /HLA-DR + than lung cancer without lymph node metastasis (P < 0. 01). Distinct statistic differences were showed between CD3 + /CD25 + and CD3 + /HLA-DR + in stage III , IV and stage I , II (P < 0. 01). Histopathological grade and age were also significantly associated with the expression of CD3 + /CD25 + and CD3 + /HLA-DR
+ ( P < 0. 01 or P < 0. 05). Peripheral blood CD3+ /CD25 + and CD3 + /HLA-DR + contents were not related with squamous carcinoma , adenocarcinoma and gender. There was no significance difference between the expression of CD3 + /CD25 + and CD3+ /HLA-DR + in benign lesions and normal donors. CD3 + /CD25 + and CD3 + /HLA-DR + in T lymphocyte with post-operation were significantly higher than those in pre-operation ( P < 0. 01 or P < 0. 05 ). There was no significance difference between the expression of CD3
+ /CD25 + and CD3 +/HLA-DR + in one week after operation and in one month after operation. Conclusion: Detection of CD3 +/ CD25 + and CD3 + /HLA-DR + levels by flow cytometry might be helpful for reflecting the human immunity function, condition judgement, prognosis evaluation and immune treatment in patients with non-small cell lung cancer.
出处
《临床肿瘤学杂志》
CAS
2003年第6期413-416,共4页
Chinese Clinical Oncology
